skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Incretins and the specific mechanism of action of liraglutide, the first applicable human glucagon-like peptide 1 analog in the treatment of type 2 diabetes

Review

(1611) Views  (566) Full article downloads

Authors: Edoardo Mannucci, Caterina Lamanna

Published Date September 2010 Volume 2010:3 Pages 105 - 112
DOI: http://dx.doi.org/10.2147/JRLCR.S6345

Edoardo Mannucci, Caterina Lamanna
Diabetes Agency, Careggi Teaching Hospital, Florence, Italy

Abstract: Liraglutide is a once-daily glucagon-like peptide 1 (GLP-1) receptor agonist, approved for use as a treatment of type 2 diabetes. Like other drugs of the same class, liraglutide stimulates insulin secretion in a glucose-dependent fashion, has the potential of preventing β-cell mass decline, and inhibits food intake. In addition, experimental studies suggest that the GLP-1 receptor agonists could protect myocardium from ischemic injury, enhancing cardiac function. In clinical trials, liraglutide (in monotherapy or as add-on to 1 or 2 oral drugs) is as effective as, or more effective than, other agents (sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, insulin, and exenatide) in reducing hemoglobin A1c; induces weight loss; and has a blood pressure-lowering effect. The possible beneficial cardiovascular effects need to be confirmed by specifically designed long-term studies.

Keywords: liraglutide, type 2 diabetes, GLP-1 receptor agonist






Readers of this article also read:

Epigenetic modifications of embryonic stem cells: current trends and relevance in developing regenerative medicine
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases
Pharmacological characterization of oxime agonists of the histamine H4 receptor
Overview of the LDL receptor: relevance to cholesterol metabolism and future approaches for the treatment of coronary heart disease
Mirtogenol® potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
Modularity in receptor evolution: insulin- and glucagon-like peptide modules as binding sites for insulin and glucose in the insulin receptor
Hydrophobicity profiles in G protein-coupled receptor transmembrane helical domains
Microscope-controlled glass bead blasting: a new technique
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy